Skye Bioscience, Inc. Common Stock (SKYE) — Cash Flow-to-Debt Ratio
Skye Bioscience, Inc. Common Stock (SKYE) has a Cash Flow-to-Debt Ratio of -1.18x as of December 2025, meaning its operating cash flow of $-9.77 Million could theoretically repay -1% of its total liabilities ($8.29 Million) in one year. See Skye Bioscience, Inc. Common Stock free cash flow generation to measure how efficiently the company converts operating cash flow to free cash.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Skye Bioscience, Inc. Common Stock Cash Flow-to-Debt Ratio (2012–2025)
Historical debt coverage capacity for Skye Bioscience, Inc. Common Stock across 14 annual periods. Also explore Skye Bioscience, Inc. Common Stock annual equity growth to track the company's year-over-year net asset growth rate.
Annual Cash Flow-to-Debt Ratio for Skye Bioscience, Inc. Common Stock (2012–2025)
Year-by-year debt coverage analysis for Skye Bioscience, Inc. Common Stock. For market capitalisation and broader financial context, see Skye Bioscience, Inc. Common Stock stock valuation.
| Year | CF-to-Debt Ratio | Operating CF (USD) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | -5.19x | $-43.06 Million | $8.29 Million | ▲ +5.1% |
| 2024 | -5.47x | $-25.24 Million | $4.61 Million | ▼ -451.9% |
| 2023 | -0.99x | $-13.95 Million | $14.07 Million | ▲ +5.7% |
| 2022 | -1.05x | $-12.74 Million | $12.12 Million | ▲ +35.2% |
| 2021 | -1.62x | $-6.47 Million | $3.99 Million | ▲ +40.5% |
| 2020 | -2.73x | $-6.05 Million | $2.22 Million | ▲ +34.5% |
| 2019 | -4.16x | $-6.03 Million | $1.45 Million | ▼ -1748.8% |
| 2018 | -0.23x | $-3.94 Million | $17.52 Million | ▲ +90.7% |
| 2017 | -2.43x | $-3.30 Million | $1.36 Million | ▼ -21.3% |
| 2016 | -2.00x | $-3.55 Million | $1.77 Million | ▼ -63.3% |
| 2015 | -1.23x | $-3.73 Million | $3.04 Million | ▲ +44.0% |
| 2014 | -2.19x | $-1.76 Million | $801.89K | ▼ -2650.6% |
| 2013 | -0.08x | $-14.49K | $182.15K | ▼ -117.9% |
| 2012 | 0.45x | $1.93K | $4.33K | — |